Brazil has temporarily suspended the administration of the world’s first single-dose dengue vaccine following two suspected deaths and several severe adverse reactions. According to Health Minister Alexandre Padilha, the pause is a precautionary measure while officials investigate whether the vaccine, developed by the public Butantan Institute, is linked to these cases.
- Vaccinations administered: Approximately 501,000 people between January and May.
- Reported symptoms: Roughly 3,700 individuals (0.7%) experienced dengue-like symptoms.
- Severe cases: 42 severe reactions, including two deaths and one ICU admission.
- Clinical trial benchmark: 91.6% efficacy against severe disease in trials with over 16,000 volunteers.
Why the Vaccine Was Suspended
The Brazilian government announced the suspension on Monday after identifying three critical cases among those vaccinated. Two of these cases resulted in the deaths of a 58-year-old man and a 48-year-old woman. A third patient, a 38-year-old woman, was admitted to intensive care but has since been discharged.
While the suspension is immediate, health officials emphasized that a definitive link has not yet been proven. In a press conference, Health Minister Alexandre Padilha stated:
“No existen datos suficientes para establecer una relación causal entre la vacuna y estos tres casos graves, pero es una señal de alerta.”
— Alexandre Padilha, Minister of Health
Padilha noted that the decision to pause the rollout was made out of “precaución,” as the severe reactions represent roughly 8 cases per 100,000 people.
Breakdown of Adverse Reactions
The vaccine rollout primarily targeted healthcare professionals. Between January and May, about 501,000 people received the dose. Of that group, approximately 3,700 people reported symptoms mirroring those of the dengue virus itself, which typically include high fever, muscle pain, headaches, nausea, and skin rashes.
Of the 42 individuals who experienced more severe reactions, the majority recovered, though the three critical cases mentioned above triggered the current federal investigation. Dengue is transmitted to humans via the tiger mosquito and, while often manageable, can be fatal in exceptional circumstances.
Contrast With Clinical Trial Data
The current adverse events were described by Minister Padilha as “totally unexpected.” During the vaccine’s clinical trial phase, which involved more than 16,000 volunteers, these specific severe reactions were not observed. Furthermore, those trials demonstrated a 91.6% efficacy rate in preventing the most severe forms of the disease.
The vaccine had received approval from health authorities in November, marking a significant step in dengue prevention due to its single-dose requirement, unlike other multi-dose regimens.
